Pacific Biosciences of California, Inc. (NASDAQ:PACB) produced a 10.79% rally since recording the worst price of $3.11. Thanks to the latest -2.27% decrease, it now trades at $3.44. Throughout the trading on Jul. 14, 2017, the share price floated between $3.42 and $3.58. This company shares are 96.8% off its target price of $6.77 and the current market capitalization stands at $385.62M. The recent change has given its price a -5.23% deficit over SMA 50 and -63.79% deficit over its 52-week high. The stock witnessed 2.99% gains, -29.07% declines and -26.65% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found PACB’s volatility during a week at 5.31% and during a month it has been found around 5.46%.Pacific Biosciences of California, Inc. (PACB) Top Holders
Institutional investors currently hold around $224 million or 68.1% in PACB stock. Look at its top three institutional owners. Maverick Capital Ltd owns $31.94 million in Pacific Biosciences of California, Inc., which represents roughly 8.28% of the company’s market cap and approximately 14.26% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 8,005,472 shares of the stock are valued at $28.18 million. The third largest holder is Oracle Investment Management Inc, which currently holds $19.38 million worth of this stock and that ownership represents nearly 5.03% of its market capitalization.Pacific Biosciences of California, Inc. 13F Filings
At the end of March 2017 reporting period, 49 institutional holders increased their position in Pacific Biosciences of California, Inc. (NASDAQ:PACB) by some 13,109,880 shares, 58 decreased positions by 13,076,734 and 22 held positions by 37,419,823. That puts total institutional holdings at 63,606,437 shares, according to SEC filings. The stock grabbed 19 new institutional investments totaling 8,087,492 shares while 23 institutional investors sold out their entire positions totaling 3,163,703 shares.
Multiple company employees have indulged in significant insider trading. Pacific Biosciences of California, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that SVP, Research & Development Phillips James Michael has sold 20,000 shares of Pacific Biosciences of California, Inc. (PACB) in trading session dated Oct. 28, 2016. These shares are worth $168,800 and were traded at $8.44 each. The SEC filing shows that Phillips James Michael performed a sale of 20,000 shares. The SVP, Research & Development disposed these shares by way of transaction on Jul. 29, 2016. The company’s shares were given away at $8.45 per share worth to an income of some $169,000 on account of Phillips James Michael.
SVP, Research & Development, Phillips James Michael, sold 20,000 common shares of Pacific Biosciences of California, Inc. (PACB) in the open market. In a transaction dated Apr. 25, 2016, the shares were put up for sale at an average price of $10.29, raking in a sum of $205,800. After this sale, 181,449 common shares of PACB are directly owned by the insider, with total stake valued at $624,185.
In the transaction dated Aug. 07, 2015, the great number of shares disposed came courtesy the SVP, Research & Development; Phillips James Michael disposed a total of 16,689 shares at an average price of $4.61, amounting to approximately $76,936. The insider now directly owns 179,160 shares worth $616,310.Pacific Biosciences of California, Inc. (PACB) Analyst Guide
Several analysts have released their opinion on Pacific Biosciences of California, Inc. (NASDAQ:PACB), with 3 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.83 average brokerage recommendation.